8 Apr 2021


“A successful biopharmaceutical company needs a pipeline of patented molecules that can become next-generation therapeutic drugs. Patent protection is one of the most important aspects of safeguarding the company`s assets and shareholder investments,” commented Dr. Guy Chamberland, CEO and CRO of Tetra. Confluence Pharmaceuticals and AOP Orphan Pharmaceuticals AG recently announced that they have signed a final agreement for the co-development and marketing of confluence`s main asset, a product to treat fragile X syndrome in Europe and the Middle East. Confluence is a biopharmaceutical company focused on the development of therapeutic treatments for fragile X syndrome and autism spectrum disorders. AOP is an Austrian company specializing in the development and marketing of medicines for rare and complex diseases. OTTAWA, February 27, 2020 (GLOBE NEWSWIRE) — Tetra Bio-Pharma. (“Tetra” or “the company”) (TSX-V: TBP) (OTCQB: TBPMF), a leading provider of cannabinoids, depreciated drugs, is pleased to announce that it has signed a clear agreement with MAKScientific on co-development. This agreement allows Tetra to access new patented molecules with CB1 and CB2 agonist or antagonistic properties. In the long term, this agreement will ensure the introduction of new patented pharmaceutical products for Tetra, which can develop after Caumz and QIXLEEF have obtained marketing approval. The analysis of actual contractual agreements allows us to assess the following: MAKScientific is a recognized world leader in endocannabinoid research and drug development. MAKScientific has developed a pipeline of small molecular drugs that target cannabinoid receptors (CB1 and CB2) as well as other targets involved in the endocannabinoid system.

As part of this agreement, MAKScientific will develop new molecules that will be evaluated by Tetra to detect possible efficacy in various indications such as cancer, pain and inflammation, as well as other potential Tetra targets. Through Confluence Pharmaceuticals, Inc. Confluence Pharmaceuticals, an Indianapolis-based company developed in Indianapolis, IN, new treatments for nuclear damage related to fragile X syndrome and autism spectrum disorders. Dr. Craig A. Erickson started a foundation work at Indiana University and the original IP was granted exclusively to Confluence of Indiana University. Confluence has assembled a team of industry experts with experience in drug development, clinical trials and regulatory issues to accelerate the development of new drugs and formulations for FXS and ASD.

Comments are closed.